Rate My Professor Navin Varadarajan

Varadarajan's research specializes in single-cell analysis, cancer immunotherapy, and proteases. Directing the Single-Cell Lab, his group develops high-throughput microfluidic assays and imaging platforms, such as the TIMING process, to quantify dynamic immune cell interactions, T cell cytotoxicity, and antigen-specific responses at the single-cell level. These tools enable functional profiling of immune responses in cancer, autoimmune diseases, and infectious diseases, facilitating the engineering of therapeutic antibodies, enzymes, and vaccines. His work has led to over 4,400 citations on Google Scholar and commercialization efforts, including co-founding CellChorus to advance single-cell immune profiling technologies and licensing intranasal vaccine platforms to AuraVax Therapeutics for SARS-CoV-2 and influenza prevention. Varadarajan was elected a Senior Member of the National Academy of Inventors in 2022 and received the Stewart R. Rahr Melanoma Research Alliance Young Investigator Award in 2013. He has secured significant funding, including a Cancer Prevention & Research Institute of Texas grant, and holds multiple patents in biotechnology.